
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 16, 2014

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of
incorporation)

333-184881

(Commission File Number)

45-5401931

(IRS Employer Identification No.)

546 Fifth Avenue, 14th Floor
New York, NY

(Address of principal executive offices)

10036

(Zip Code)

Registrant's telephone number, including area code **(212) 702-7163**

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

On October 16, 2014, Relmada Therapeutics, Inc. (the "Company") issued a press release announcing the gross proceeds received from the exercise of its Series A Warrants issued in May and June 2014. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Relmada Therapeutics, Inc., Press Release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 16, 2014

RELMADA THERAPEUTICS, INC.

By: /s/ Sergio Traversa
Name: Sergio Traversa
Title: Chief Executive Officer

RELMADA THERAPEUTICS REINFORCES BALANCE SHEET WITH \$15.2 MILLION FROM EXERCISE OF WARRANTS

Additional Capital Enable Company to Achieve Additional Milestones in its Business Plan

New York, NY October 16, 2014 – Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014. The warrants were exercised at \$1.50 per share, resulting in gross proceeds of approximately \$15.2M for the Company.

Sergio Traversa, CEO of Relmada, stated, “These additional funds reinforce Relmada’s already healthy balance sheet and will allow us to expedite the development of our pain treatment drugs. We have an ambitious strategy, and these funds enhance our flexibility in implementing our plans and reaching the planned milestones.”

Relmada is currently developing LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-methadone, its NMDA receptor antagonist for neuropathic pain.; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical stage, publicly traded specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at different stages of development. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisory board. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information on Relmada, log on to <http://www.relmada.com>.

Forward-Looking Statements

This news release contains "forward-looking statements". These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact

Sergio Traversa, CEO
Relmada Therapeutics Inc.
Tel: 212-702-7165
straversa@relmada.com

Media contact:

Janet Vasquez
JV Public Relations NY
Tel: 212-645-5498
jvasquez@jvprny.com